期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

美国临床肿瘤学会HER2阳性进展期乳腺癌系统治疗临床实践指南(2018)更新解读 被引量：8

Updated interpretation of the American society of clinical oncology's clinical practice guideline for systematic treatment of her2 positive advanced breast cancer(2018 edition)
在线阅读 下载PDF
导出
摘要 HER2阳性乳腺癌是一种特殊类型的乳腺癌,恶性程度高,预后差。曲妥珠单抗的问世,改变了HER2阳性乳腺癌的疾病自然进程。正因如此,规范HER2阳性进展期乳腺癌病人的治疗更为重要。美国临床肿瘤学会(ASCO)曾于2014年发表了HER2阳性进展期乳腺癌系统治疗的临床实践指南,对临床产生广泛影响[1].
作者 佟仲生 TONG Zhongsheng
机构地区 天津医科大学肿瘤医院乳腺肿瘤内科
出处 《临床外科杂志》 2019年第1期17-20,共4页 Journal of Clinical Surgery
基金 天津市科委抗癌重大专项资助项目(12ZCDZSY16200) 天津市卫计委攻关资助项目(16KG128)
关键词 HER2阳性 乳腺癌 曲妥珠单抗 ASCO指南
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献30

  • 1Wolff AC, Hammond MEH,Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. ArchPathol Lab Med, 2013,138(2) : 241-256. DOI: 10. 5858/arpa.2013-0953-SA.
  • 2Fabi A, Di Benedetto A, Metro G,et al. HER2 protein and genevariation between primary and metastaticbreast cancer :significance and impact on patient care. Clin Cancer Res, 2011,17(7) : 2055-2064. DOI: 10.1158/1078-0432. CCR-10-1920.
  • 3Robert N,Leylan-Jones B, Asmar L, et al. Randomized phase Idstudy of trastuzumab, paclitaxel, and carboplatin compared withtrastuzumab and paclitaxel in women with HER-2 -overexpressingmetastatic breast cancer[ J]. J Clin Oncol, 2006, 24(18) : 2786-2792.
  • 4Wardley AM, Pivot X,Morales-Vasquez F, et al. Randomizedphase II trial of first-line trastuzumab plus docetaxel andcapecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [ J ]. J Clin Oncol,2010,28(6): 976-983. DOI: 10.1200/JC0.2008.21.6531.
  • 5Andersson M, Lidbrink E, Bjerre K, et al. Phase HI randomizedstudy comparing docetaxel plus trastuzumab with vinorelbine plustrastuzumab as first-line therapy of metastatic or locally advancedhuman epidermal growth factor receptor 2-positive breast cancer:The HERNATA study [J]. J Clin Oncol, 2011, 29 ( 3 ) : 264-271. DOI: 10.12OO/JCO. 2010. 30. 8213.
  • 6Schaller G, Fuchs I, Gonsch T,et al. Phase U Study ofCapecitabine Plus Trastuzumab in Human Epidermal GrowthFactor Receptor 2 -Overexpressing Metastatic Breast CancerPretreated With Anthracyclines or Taxanes [ J ]. J Clin Oncol,2007, 25(22) : 3246-3250.
  • 7Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabineand trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer[ J]. Clin Breast Cancer,2009 , 9(3) : 178-183. DOI: 10.3816/CBC.2009. n. 029.
  • 8Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab,and docetaxel in HER2-positive metastatic breast cancer [ J ] . NEngl J Med, 2015,372 ( 8 ) : 724-734. DOI: 10. 1056/NEJMoal413513.
  • 9Kaufman B, Mackey JR,Clemens MR,et al. Trastuzumab plusanastrozole versus anastrozole alone for the treatment ofpostmenopausal women with human epidermal growth factorreceptor 2-positive, hormone receptor-positive metastatic breastcancer : Results from the randomized phase ]H TAnDEM study[J]. J Clin Oncol, 2009, 27(33) : 5529-5537. DOI: 10. 1200/JCO.2008.20.6847.
  • 10Johnston S, Pippen J, Pivot X, et al. Lapatinib combined withletrozole versus letrozole and placebo as first-line therapy forpostmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2009, 27(33) : 5538-5546. 10.1200/jc0.2009.23.3734.

共引文献76

同被引文献117

引证文献8

二级引证文献96

临床外科杂志
2019年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部